Ligand Pharma (LGND) Posts Q3 Loss of 3c, Tops by 1c; Guides
LGND Hot Sheet
Revenue Growth %: +43.6%Financial Fact:
Other, net: 254K
Today's EPS Names:
TNP, MENT, More
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reports Q3 loss of $0.03, 1 cents better than the analyst estimate of ($0.04). Revenue for the quarter was $7.9 million, which compares to the estimate of $7.08 million.
Sees FY09 sales $33 - $34 million, versus $34.30 million consensus.
Sees FY09 sales $33 - $34 million, versus $34.30 million consensus.
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Patterson Companies, Inc. (PDCO) Tops Q4 EPS by 5c; Guides FY12
- Synopsys, Inc. (SNPS) Misses Q2 EPS by 2c; Issues Confident Q3 Outlook; Guides FY12
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
